AKRO
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
1.87B
GET INTRADAY SIGNALS
AKRO Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
54 days until earnings call
+Compare
AKRO
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
1.87B

AKRO Price Prediction, Akero Therapeutics AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
AKRO Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Mar 23, 2023

AKRO in downward trend: price dove below 50-day moving average on March 09, 2023

AKRO moved below its 50-day moving average on March 09, 2023 date and that indicates a change from an upward trend to a downward trend. In 30 of 33 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 09, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on AKRO as a result. In of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for AKRO turned negative on March 10, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKRO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AKRO broke above its upper Bollinger Band on March 01, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AKRO entered a downward trend on March 14, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AKRO's RSI Oscillator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AKRO advanced for three days, in of 210 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AKRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.731) is normal, around the industry mean (21.708). P/E Ratio (0.000) is within average values for comparable stocks, (125.534). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.749). Dividend Yield (0.000) settles around the average of (0.028) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (303.071).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

AI
A.I. Advisor
published Earnings

AKRO is expected to report earnings to rise 76.82% to -86 cents per share on May 17

Akero Therapeutics AKRO Stock Earnings Reports
Q1'23
Est.
$-0.87
Q4'22
Beat
by $0.29
Q3'22
Missed
by $0.16
Q2'22
Beat
by $0.07
Q1'22
Beat
by $0.06
The last earnings report on March 17 showed earnings per share of -49 cents, beating the estimate of -78 cents. With 1.42M shares outstanding, the current market capitalization sits at 1.87B.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.96B. The market cap for tickers in the group ranges from 160 to 331.75B. NONOF holds the highest valuation in this group at 331.75B. The lowest valued company is CDXI at 160.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 0%. CALC experienced the highest price growth at 1,040%, while MMIRF experienced the biggest fall at -92%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was -33% and the average quarterly volume growth was -64%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 62
SMR Rating: 92
Profit Risk Rating: 94
Seasonality Score: -2 (-100 ... +100)
AI
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published General Information

General Information

a biotechnology company, which specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
601 Gateway Boulevard
Phone
+1 650 487-6488
Employees
33
Web
https://www.akerotx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MECEX10.810.08
+0.75%
MainStay Epoch Capital Growth C
ESGMX15.690.07
+0.45%
Mirova Global Sustainable Equity A
AMFCX45.890.01
+0.02%
American Funds American Mutual C
LCBVX35.19-0.13
-0.37%
ClearBridge Large Cap Value R
FAMDX22.44-0.13
-0.58%
FAM Small Cap Institutional

AKRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKRO has been loosely correlated with ETNB. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if AKRO jumps, then ETNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKRO
1D Price
Change %
AKRO100%
+5.04%
ETNB - AKRO
43%
Loosely correlated
+23.83%
ADTX - AKRO
32%
Poorly correlated
-2.48%
IMRX - AKRO
32%
Poorly correlated
+1.37%
NRBO - AKRO
30%
Poorly correlated
-0.73%
XNCR - AKRO
28%
Poorly correlated
+3.16%
More